|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
|
US7393682B1
(en)
|
1993-03-19 |
2008-07-01 |
The Johns Hopkins University School Of Medicine |
Polynucleotides encoding promyostatin polypeptides
|
|
US6180134B1
(en)
*
|
1993-03-23 |
2001-01-30 |
Sequus Pharmaceuticals, Inc. |
Enhanced ciruclation effector composition and method
|
|
US5540935A
(en)
*
|
1993-12-06 |
1996-07-30 |
Nof Corporation |
Reactive vesicle and functional substance-fixed vesicle
|
|
US6132764A
(en)
*
|
1994-08-05 |
2000-10-17 |
Targesome, Inc. |
Targeted polymerized liposome diagnostic and treatment agents
|
|
US5512294A
(en)
*
|
1994-08-05 |
1996-04-30 |
Li; King C. |
Targeted polymerized liposome contrast agents
|
|
US5885613A
(en)
*
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
|
US5820873A
(en)
*
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
|
US6673364B1
(en)
|
1995-06-07 |
2004-01-06 |
The University Of British Columbia |
Liposome having an exchangeable component
|
|
DE69629702T2
(de)
*
|
1995-08-01 |
2004-06-17 |
Isis Pharmaceuticals, Inc., Carlsbad |
Liposomale oligonukleotidzusammensetzungen
|
|
US5908624A
(en)
*
|
1996-06-27 |
1999-06-01 |
Albany Medical College |
Antigenic modulation of cells
|
|
US6245349B1
(en)
|
1996-02-23 |
2001-06-12 |
éLAN CORPORATION PLC |
Drug delivery compositions suitable for intravenous injection
|
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US7812149B2
(en)
*
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
|
US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
|
US8007784B1
(en)
|
1996-06-27 |
2011-08-30 |
Albany Medical College |
Antigenic modulation of cells
|
|
US6294614B1
(en)
|
1996-07-29 |
2001-09-25 |
K. K. Vayu |
Modified polymers containing poly(2-hydroxyethyl(meth)acrylate segment in the molecule
|
|
US6284267B1
(en)
|
1996-08-14 |
2001-09-04 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
|
US7368129B1
(en)
|
1996-08-14 |
2008-05-06 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
|
TW520297B
(en)
*
|
1996-10-11 |
2003-02-11 |
Sequus Pharm Inc |
Fusogenic liposome composition and method
|
|
US6056973A
(en)
*
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
|
ES2125817B1
(es)
*
|
1997-01-20 |
2000-01-01 |
Consejo Superior Investigacion |
Obtencion de nuevos cristales liquidos polimeros capaces de interaccionar con liposomas.
|
|
US5827533A
(en)
*
|
1997-02-06 |
1998-10-27 |
Duke University |
Liposomes containing active agents aggregated with lipid surfactants
|
|
DE19726186A1
(de)
*
|
1997-06-20 |
1998-12-24 |
Boehringer Ingelheim Int |
Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
|
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
|
US6197332B1
(en)
|
1997-08-13 |
2001-03-06 |
Chiron Corporation |
Lipid-conjugated polyamide compounds and related compositions and methods thereof
|
|
US6734171B1
(en)
|
1997-10-10 |
2004-05-11 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating nucleic acids in lipid bilayers
|
|
US6083923A
(en)
*
|
1997-10-31 |
2000-07-04 |
Isis Pharmaceuticals Inc. |
Liposomal oligonucleotide compositions for modulating RAS gene expression
|
|
US6986902B1
(en)
*
|
1998-04-28 |
2006-01-17 |
Inex Pharmaceuticals Corporation |
Polyanionic polymers which enhance fusogenicity
|
|
US20030215421A1
(en)
*
|
1999-07-21 |
2003-11-20 |
Mcdonald John R. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
|
US7157418B1
(en)
|
1998-07-22 |
2007-01-02 |
Osprey Pharmaceuticals, Ltd. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
|
CA2346879A1
(fr)
*
|
1998-09-16 |
2000-04-27 |
Alza Corporation |
Inhibiteurs de topoisomerase pieges dans des liposomes
|
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
|
US6379698B1
(en)
|
1999-04-06 |
2002-04-30 |
Isis Pharmaceuticals, Inc. |
Fusogenic lipids and vesicles
|
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
|
US6251927B1
(en)
*
|
1999-04-20 |
2001-06-26 |
Medinox, Inc. |
Methods for treatment of sickle cell anemia
|
|
US7303760B2
(en)
*
|
1999-04-23 |
2007-12-04 |
Alza Corporation |
Method for treating multi-drug resistant tumors
|
|
EP1880736A1
(fr)
*
|
1999-04-23 |
2008-01-23 |
Alza Corporation |
Liaison amovible et composition la contenant
|
|
US7238368B2
(en)
*
|
1999-04-23 |
2007-07-03 |
Alza Corporation |
Releasable linkage and compositions containing same
|
|
US7112337B2
(en)
|
1999-04-23 |
2006-09-26 |
Alza Corporation |
Liposome composition for delivery of nucleic acid
|
|
EP1059092B1
(fr)
*
|
1999-06-08 |
2005-12-07 |
Gentium S.p.A. |
Utilisation de complexes de liposomes cationiques et de polydéoxyribonucléotides comme médicaments
|
|
GB9918670D0
(en)
|
1999-08-06 |
1999-10-13 |
Celltech Therapeutics Ltd |
Biological product
|
|
US20020064520A1
(en)
*
|
1999-08-19 |
2002-05-30 |
Yanina Rozenberg |
Targeted artificial gene delivery
|
|
US20040197390A1
(en)
*
|
2001-05-29 |
2004-10-07 |
Shi-Kun Huang |
Neutral-cationic lipid for systemic delivery of factor VIII gene
|
|
AU7868400A
(en)
*
|
1999-10-08 |
2001-04-23 |
Alza Corporation |
Neutral-cationic lipid for nucleic acid and drug delivery
|
|
WO2001041738A2
(fr)
*
|
1999-12-10 |
2001-06-14 |
Celator Technologies Inc. |
Compositions d'excipient a base de lipides ayant des fonctions de reaction au moyen d'une surface protegee
|
|
CN101041079A
(zh)
*
|
1999-12-30 |
2007-09-26 |
诺瓦提斯公司 |
用于基因治疗的新的胶体合成载体
|
|
US20040009229A1
(en)
*
|
2000-01-05 |
2004-01-15 |
Unger Evan Charles |
Stabilized nanoparticle formulations of camptotheca derivatives
|
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
|
US7230088B2
(en)
|
2001-07-03 |
2007-06-12 |
Mallinckrodt, Inc. |
Compounds for dual photodiagnosis and therapy
|
|
ES2236181T3
(es)
*
|
2000-01-28 |
2005-07-16 |
Alza Corporation |
Liposomas que contienen un compuesto atrapado en una solucion supersaturada.
|
|
US20010042099A1
(en)
*
|
2000-02-02 |
2001-11-15 |
Doongo Technologies, Inc. |
Apparatus and methods for optimizing traffic volume in wireless email communications
|
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
|
US7118737B2
(en)
*
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
|
CN1458846A
(zh)
*
|
2000-09-08 |
2003-11-26 |
格莱风治疗公司 |
促红细胞生成性合成蛋白
|
|
US6673334B1
(en)
*
|
2000-10-16 |
2004-01-06 |
Mallinkcrodt, Inc. |
Light sensitive compounds for instant determination of organ function
|
|
US6656451B1
(en)
*
|
2000-10-16 |
2003-12-02 |
Mallinckrodt, Inc. |
Indole compounds as novel dyes for organ function monitoring
|
|
US6669926B1
(en)
*
|
2000-10-16 |
2003-12-30 |
Mallinckrodt, Inc. |
Hydrophilic light absorbing indole compounds for determination of physiological function in critically ill patients
|
|
US7045283B2
(en)
|
2000-10-18 |
2006-05-16 |
The Regents Of The University Of California |
Methods of high-throughput screening for internalizing antibodies
|
|
WO2002046372A1
(fr)
|
2000-12-08 |
2002-06-13 |
Invitrogen Corporation |
Methodes et compositions destinees a la synthese de molecules d'acide nucleique a l'aide de sites de reconnaissance multiples
|
|
US6897196B1
(en)
*
|
2001-02-07 |
2005-05-24 |
The Regents Of The University Of California |
pH sensitive lipids based on ortho ester linkers, composition and method
|
|
US20020142304A1
(en)
*
|
2001-03-09 |
2002-10-03 |
Anderson Daniel G. |
Uses and methods of making microarrays of polymeric biomaterials
|
|
DE60218154T2
(de)
*
|
2001-06-01 |
2007-10-31 |
Astellas Pharma Europe B.V. |
Lipid-polymer konjugaten
|
|
CA2633595A1
(fr)
|
2001-06-20 |
2003-01-03 |
Genentech, Inc. |
Anticorps contre des polypeptides de cibles antigeniques associees a une tumeur
|
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
AU2002315393A1
(en)
|
2001-06-21 |
2003-01-08 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
|
KR101008758B1
(ko)
|
2001-09-18 |
2011-01-14 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
|
AU2002334895B2
(en)
|
2001-10-09 |
2006-10-19 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
|
WO2003040399A2
(fr)
*
|
2001-11-02 |
2003-05-15 |
Intradigm Corporation |
Procedes therapeutiques pour vehicules d'administration d'acides nucleiques
|
|
AU2002368202B2
(en)
|
2001-11-02 |
2008-06-05 |
Insert Therapeutics, Inc |
Methods and compositions for therapeutic use of RNA interference
|
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
KR100801388B1
(ko)
|
2002-01-02 |
2008-02-05 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
|
EP1485076A1
(fr)
*
|
2002-02-27 |
2004-12-15 |
The Ohio State University Research Foundation |
Methodes de traitement de la leucemie myeloide aigue
|
|
US20050260259A1
(en)
*
|
2004-04-23 |
2005-11-24 |
Bolotin Elijah M |
Compositions for treatment with glucagon-like peptide, and methods of making and using the same
|
|
ATE494010T1
(de)
*
|
2002-02-27 |
2011-01-15 |
Pharmain Corp |
Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
|
|
US7635463B2
(en)
*
|
2002-02-27 |
2009-12-22 |
Pharmain Corporation |
Compositions for delivery of therapeutics and other materials
|
|
AU2003220277A1
(en)
*
|
2002-03-12 |
2003-09-29 |
The Johns Hopkins University School Of Medicine |
Manganese ion regulation of reverse transcriptase activity and methods of modulating same
|
|
US20080220075A1
(en)
*
|
2002-03-20 |
2008-09-11 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
|
DE60309300T3
(de)
*
|
2002-03-20 |
2011-02-24 |
Elan Pharma International Ltd. |
Nanopartikelzusammensetzungen von angiogeneseinhibitoren
|
|
JP4480402B2
(ja)
*
|
2002-03-29 |
2010-06-16 |
日油株式会社 |
リン脂質誘導体
|
|
NZ535925A
(en)
|
2002-04-16 |
2008-06-30 |
Genentech Inc |
An isolated antibody that binds to a particular polypeptide
|
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
|
US7718160B2
(en)
|
2002-07-02 |
2010-05-18 |
The Board Of Regents Of The University Of Texas System |
Radiolabeled compounds and liposomes and their method of making and using same
|
|
AU2003267785C1
(en)
|
2002-09-13 |
2009-12-24 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
|
WO2004031350A2
(fr)
|
2002-09-26 |
2004-04-15 |
Amgen, Inc. |
Modulation de l'expression du gene forkhead box o1a
|
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
|
US20040062748A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
|
EP1550675B1
(fr)
*
|
2002-09-30 |
2008-01-02 |
Nof Corporation |
Derive de phospholipide
|
|
US7879351B2
(en)
*
|
2002-10-29 |
2011-02-01 |
Transave, Inc. |
High delivery rates for lipid based drug formulations, and methods of treatment thereof
|
|
US7718189B2
(en)
|
2002-10-29 |
2010-05-18 |
Transave, Inc. |
Sustained release of antiinfectives
|
|
ES2439727T3
(es)
*
|
2002-10-29 |
2014-01-24 |
Insmed Incorporated |
Liberación sostenida de antiinfectantes
|
|
WO2004110345A2
(fr)
*
|
2002-10-29 |
2004-12-23 |
Pharmacia Corporation |
Genes exprimes de maniere differenciee impliques dans le cancer, polypeptides codes par ces genes, et methodes d'utilisation des genes
|
|
EP1560840B1
(fr)
*
|
2002-11-05 |
2015-05-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprenant des nucleosides modifies en 2' de substitution destinees a la modulation de gene
|
|
CA2504720C
(fr)
|
2002-11-05 |
2013-12-24 |
Isis Pharmaceuticals, Inc. |
Composes oligomere chimeres et leur utilisation dans la modulation genique
|
|
DK2336318T3
(da)
|
2002-11-13 |
2013-07-15 |
Genzyme Corp |
Antisense-modulering af apolipoprotein b-ekspression
|
|
EP1569695B1
(fr)
|
2002-11-13 |
2013-05-15 |
Genzyme Corporation |
Modulation antisens de l'expression d'apolipoproteine b
|
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
|
JP2006517917A
(ja)
*
|
2002-12-19 |
2006-08-03 |
アルザ・コーポレーシヨン |
血管新生性の組織増殖の治療方法
|
|
WO2004060299A2
(fr)
*
|
2002-12-26 |
2004-07-22 |
Mountain View Pharmaceuticals, Inc. |
Conjugues polymeres d'interferon-beta presentant une activite biologique accrue
|
|
CA2511815A1
(fr)
*
|
2002-12-26 |
2004-07-22 |
Mountain View Pharmaceuticals, Inc. |
Conjugues polymeres de cytokines, de chimiomokines, de facteurs de croissance, d'hormones polypeptidiques et d'antagonistes de ceux-ci conservant une activite de liaison aux recepteurs
|
|
JP4403303B2
(ja)
*
|
2003-01-06 |
2010-01-27 |
日油株式会社 |
リン脂質誘導体及びその製造方法
|
|
JP2006517790A
(ja)
*
|
2003-01-09 |
2006-08-03 |
インヴィトロジェン コーポレーション |
ポリペプチド−核酸複合体の細胞の送達および活性化
|
|
CA2515484C
(fr)
|
2003-02-11 |
2011-09-20 |
Antisense Therapeutics Ltd |
Modulation de l'expression du recepteur du facteur de croissance i analogue a l'insuline
|
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
|
US7871607B2
(en)
*
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
CA2517145C
(fr)
*
|
2003-03-05 |
2017-08-01 |
Halozyme, Inc. |
Glycoproteine hyaluronidase soluble (shasegp), procede de fabrication et compositions pharmaceutiques contenant ladite proteine
|
|
US20060104968A1
(en)
*
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
|
US7968115B2
(en)
|
2004-03-05 |
2011-06-28 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of cancer
|
|
JP4526479B2
(ja)
*
|
2003-03-20 |
2010-08-18 |
日油株式会社 |
リン脂質誘導体
|
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
|
EP1610763A2
(fr)
*
|
2003-03-31 |
2006-01-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Ensembles de lipides contenant des amphiphiles de formation non liposomique
|
|
CA2520864A1
(fr)
|
2003-03-31 |
2004-10-21 |
Alza Corporation |
Particules lipidiques presentant un revetement lipidique asymetrique et procede de preparation associe
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
AU2004231740A1
(en)
*
|
2003-04-17 |
2004-11-04 |
The Trustees Of Columbia University In The City Ofnew York |
Desmoglein 4 is a novel gene involved in hair growth
|
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
|
US7541344B2
(en)
|
2003-06-03 |
2009-06-02 |
Eli Lilly And Company |
Modulation of survivin expression
|
|
US20040247624A1
(en)
*
|
2003-06-05 |
2004-12-09 |
Unger Evan Charles |
Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
|
|
WO2005044976A2
(fr)
*
|
2003-06-20 |
2005-05-19 |
Isis Pharmaceuticals, Inc. |
Composes oligomeres utilises pour la modulation de genes
|
|
EP1648914A4
(fr)
|
2003-07-31 |
2009-12-16 |
Regulus Therapeutics Inc |
Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
|
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
|
JP2007503514A
(ja)
*
|
2003-08-26 |
2007-02-22 |
スミスクライン・ビーチャム・コーポレイション |
グリセロールおよびポリエチレングリコールのヘテロ官能性コポリマー、そのコンジュゲートおよび組成物
|
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
|
BRPI0413930A
(pt)
|
2003-09-18 |
2006-10-24 |
Isis Pharmaceuticals Inc |
composto oligomérico ou sal farmaceuticamente aceitável deste, composição farmacêutica ou veterinária, métodos para inibir a expressão de eif4e em uma célula, tecido ou órgão, para diminuir a proliferação de uma célula em que eif4e é expressado, e para prevenir ou tratar uma condição ou doença métodos para prevenir ou diminuir a angiogênese, e o crescimento de tumor em um paciente, oligonucleotìdeo de anti-sentido, composição farmacêutica ou veterinária, e, uso de um composto oligomérico ou sal farmaceuticamente aceitável deste
|
|
PT1678194E
(pt)
|
2003-10-10 |
2013-09-30 |
Alchemia Oncology Pty Ltd |
Modulação da síntese e degradação de hialuronano no tratamento de doença
|
|
EP1677765A1
(fr)
*
|
2003-10-24 |
2006-07-12 |
Alza Corporation |
Preparation de particules lipidiques
|
|
US7960350B2
(en)
|
2003-10-24 |
2011-06-14 |
Ader Enterprises, Inc. |
Composition and method for the treatment of eye disease
|
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
|
ATE434431T1
(de)
*
|
2003-11-14 |
2009-07-15 |
Het Nl Kanker I The Netherland |
Pharmazeutische formulierungen mit kurzketten- sphingolipiden und ihre verwendung
|
|
NZ596984A
(en)
|
2003-11-17 |
2013-10-25 |
Genentech Inc |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
EP1691780A2
(fr)
|
2003-11-21 |
2006-08-23 |
Alza Corporation |
Administration de genes par l'intermediaire de complexe liposome/adn avec modification de surface peg clivable
|
|
JP2007520481A
(ja)
*
|
2004-01-15 |
2007-07-26 |
アルザ・コーポレーシヨン |
治療薬を送達するためのリポソーム組成物
|
|
JP2007520222A
(ja)
|
2004-01-20 |
2007-07-26 |
アイシス ファーマシューティカルズ インコーポレイテッド |
グルココルチコイドレセプター発現の調節
|
|
US7468431B2
(en)
*
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
|
US8784881B2
(en)
|
2004-03-05 |
2014-07-22 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of diseases
|
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
|
AU2005222902B2
(en)
|
2004-03-12 |
2010-06-10 |
Alnylam Pharmaceuticals, Inc. |
iRNA agents targeting VEGF
|
|
EP1730309B1
(fr)
|
2004-03-15 |
2016-05-04 |
Ionis Pharmaceuticals, Inc. |
Compositions et methodes pour optimiser le clivage d'arn par rnase h
|
|
US7187286B2
(en)
|
2004-03-19 |
2007-03-06 |
Applera Corporation |
Methods and systems for using RFID in biological field
|
|
EP1730280B1
(fr)
*
|
2004-03-26 |
2018-10-24 |
Curis, Inc. |
Modulateurs d'interference d'arn de signalisation hedgehog et leurs utilisations
|
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
|
US20050265925A1
(en)
*
|
2004-04-21 |
2005-12-01 |
Samuel Zalipsky |
Releasable linkage and compositions containing same
|
|
US20060019972A1
(en)
*
|
2004-04-27 |
2006-01-26 |
California Institute Of Technology |
Methods of treating cancer by inhibiting histone gene expression
|
|
RU2424792C2
(ru)
|
2004-05-03 |
2011-07-27 |
Хермес Байесайенсиз, Инк. |
Липосомы, используемые для доставки лекарственных средств
|
|
CA2568735A1
(fr)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Composition a double brin comprenant des brins differentiellement modifies utilises dans la modulation genetique
|
|
US20090048192A1
(en)
*
|
2004-06-03 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
|
US8394947B2
(en)
*
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
JP2008501335A
(ja)
*
|
2004-06-03 |
2008-01-24 |
アイシス ファーマシューティカルズ、インク． |
キメラギャップ化オリゴマー組成物
|
|
US7476725B2
(en)
*
|
2004-06-08 |
2009-01-13 |
Alza Corporation |
Preparation of macromolecular conjugates by four-component condensation reaction
|
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
|
US20080063702A1
(en)
*
|
2004-09-09 |
2008-03-13 |
Yechezkel Barenholz |
Liposomal Formulations Comprising an Amphipathic Weak Base Like Tempamine for Treatment of Neurodegenerative Conditions
|
|
AU2005281352B2
(en)
*
|
2004-09-09 |
2011-01-27 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Liposomal compositions of glucocorticoid and glucocorticoid derivatives
|
|
US7635754B2
(en)
*
|
2004-09-22 |
2009-12-22 |
Aerovance, Inc. |
Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
|
|
EP1804824B1
(fr)
|
2004-09-29 |
2017-01-04 |
Icahn School of Medicine at Mount Sinai |
Compositions modulant la fsh et le recepteur de la fsh et methodes inhibant la resorption osseuse osteoclastique et les pertes osseuses de l'osteoporose
|
|
JP5101288B2
(ja)
|
2004-10-05 |
2012-12-19 |
カリフォルニア インスティテュート オブ テクノロジー |
アプタマー調節される核酸及びその利用
|
|
TW200612993A
(en)
*
|
2004-10-08 |
2006-05-01 |
Alza Corp |
Lipopolymer conjugates
|
|
EP1809246B1
(fr)
*
|
2004-10-08 |
2008-07-16 |
Alza Corporation |
Procédé d insertion d un fragment associé aux lipides dans un ensemble lipidique préformé en utilisant des micro-ondes
|
|
US20060110441A1
(en)
*
|
2004-10-28 |
2006-05-25 |
Harry Wong |
Lyophilized liposome formulations and method
|
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
|
AU2005304914B2
(en)
|
2004-11-05 |
2012-02-16 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for stabilizing liposomal camptothecin formulations
|
|
CN101102752A
(zh)
*
|
2004-11-15 |
2008-01-09 |
耶路撒冷希伯来大学伊萨姆研发公司 |
联合优选为神经酰胺与细胞毒性药物的联合疗法
|
|
WO2006069344A2
(fr)
|
2004-12-22 |
2006-06-29 |
Rutgers, The State University Of New Jersey |
Hydrogels a liberation regulee
|
|
US8664392B2
(en)
|
2004-12-23 |
2014-03-04 |
Medibeacon, LLC |
Pyrazine derivatives for bioconjugation
|
|
AU2006213686A1
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
EP1869076A2
(fr)
|
2005-03-10 |
2007-12-26 |
Genentech, Inc. |
Procedes et compositions de modulation de l'integrite vasculaire
|
|
US7427605B2
(en)
|
2005-03-31 |
2008-09-23 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
|
EP1885404A2
(fr)
*
|
2005-06-01 |
2008-02-13 |
Alza Corporation |
Reactions de bioconjugaison pour acyler des reactifs de polyethylene glycol
|
|
US20070015701A1
(en)
*
|
2005-06-01 |
2007-01-18 |
Samuel Zalipsky |
Macromolecular conjugates of bone morphogenetic protein-7
|
|
WO2006138380A2
(fr)
|
2005-06-15 |
2006-12-28 |
Massachusetts Institute Of Technology |
Lipides contenant des amines et utilisations
|
|
WO2007005754A2
(fr)
*
|
2005-07-01 |
2007-01-11 |
Alza Corporation |
Vehicule d'administration de medicaments hydrophobes par liposomes
|
|
US8998881B2
(en)
|
2005-08-10 |
2015-04-07 |
Alza Corporation |
Method for delivering drugs to tissue under microjet propulsion
|
|
WO2007033110A2
(fr)
*
|
2005-09-12 |
2007-03-22 |
Alza Corporation |
Liposomes pour traiter le myélome multiple
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
CA2627585A1
(fr)
|
2005-11-01 |
2007-05-10 |
Alnylam Pharmaceuticals, Inc. |
Inhibition de la replication du virus de la grippe par interference arn
|
|
DE102005053066A1
(de)
|
2005-11-04 |
2007-05-10 |
Basf Ag |
Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
|
|
JP2009516710A
(ja)
|
2005-11-21 |
2009-04-23 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
ｅＩＦ４Ｅ−ＢＰ２の発現のモジュレート
|
|
CN101365424A
(zh)
*
|
2005-12-08 |
2009-02-11 |
耶路撒冷希伯来大学伊森姆研究发展公司 |
通过超声辐射改变脂质体组成的方法
|
|
AU2006322076C1
(en)
|
2005-12-08 |
2013-11-14 |
Insmed Incorporated |
Lipid-based compositions of antiinfectives for treating pulmonary infections
|
|
WO2007065846A2
(fr)
*
|
2005-12-09 |
2007-06-14 |
Basf Se |
Utilisation de copolymeres blocs de lactame polyvinylique et d'oxyde de polyalkylene comme solubilisants dans des composes peu solubles dans l'eau
|
|
JP2009520040A
(ja)
*
|
2005-12-19 |
2009-05-21 |
ファーマイン コーポレーション |
治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
|
|
EP2161038B1
(fr)
|
2006-01-26 |
2013-12-25 |
Isis Pharmaceuticals, Inc. |
Compositions et leurs utilisations dirigées vers la huntingtine
|
|
WO2007103250A2
(fr)
*
|
2006-03-02 |
2007-09-13 |
Mallinckrodt Inc. |
Composes de thiadiazole et utilisations desdits composes
|
|
JP2009529533A
(ja)
*
|
2006-03-10 |
2009-08-20 |
マリンクロット インコーポレイテッド |
光活性の化合物および組成物、ならびにそれらの使用方法
|
|
US20090306349A1
(en)
*
|
2006-03-31 |
2009-12-10 |
Rampak Corp |
Binding partners with immunoglobulin domains modified to have extended half-life
|
|
WO2007115168A2
(fr)
|
2006-03-31 |
2007-10-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions et méthodes destinées à inhiber l'expression du gène eg5
|
|
EP2614839A3
(fr)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Méthode d'utilisation du BOC/CDO pour moduler l'émission des signaux du hedgehog
|
|
EP2013222B1
(fr)
|
2006-04-28 |
2013-02-13 |
Alnylam Pharmaceuticals Inc. |
Compositions et procédés d'inhibition de l'expression d'un gène du virus jc
|
|
BRPI0711182A2
(pt)
*
|
2006-05-03 |
2011-08-23 |
Baltic Technology Dev |
agentes anti-sentido combinando base fortemente ligada-oligonucleotìdeo modificado e nuclease artificial
|
|
WO2007133627A2
(fr)
*
|
2006-05-10 |
2007-11-22 |
Alza Corporation |
Procédé de fabrication de conjugués de liposomes avec des ligands sensibles à la température
|
|
ATE528008T1
(de)
|
2006-05-19 |
2011-10-15 |
Alnylam Pharmaceuticals Inc |
Rnai-modulation von aha und ihre therapeutische verwendung
|
|
EP2018443A4
(fr)
|
2006-05-22 |
2009-11-11 |
Alnylam Pharmaceuticals Inc |
Compositions et méthodes inhibant l'expression du gène ikk-b
|
|
US20090209625A1
(en)
*
|
2006-05-23 |
2009-08-20 |
Sanjay Bhanot |
Modulation of chrebp expression
|
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
US20120196827A1
(en)
|
2006-06-12 |
2012-08-02 |
Oncomethylome Sciences S.A. |
Methylation markers for early detection and prognosis of colon cancers
|
|
DK2029554T3
(da)
|
2006-06-22 |
2014-06-10 |
Medibeacon Llc |
Pyrazinderivater og anvendelser heraf til nyreovervågning
|
|
WO2008011473A2
(fr)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions et leurs utilisations liées à l'hbxip
|
|
CA2600220C
(fr)
*
|
2006-09-07 |
2014-12-09 |
Canadian Blood Services |
Particules lipidiques reticulees en surface et methodes de production et utilisations connexes
|
|
US8158595B2
(en)
*
|
2006-11-09 |
2012-04-17 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
|
US8834920B2
(en)
|
2006-12-21 |
2014-09-16 |
Alza Corporation |
Liposome composition for targeting egfr receptor
|
|
WO2008079976A2
(fr)
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Constructions dimères de récepteur egf à haute affinité et utilisations correspondantes
|
|
WO2008079973A2
(fr)
*
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Peptides de liaison au récepteur egf et utilisations de ces derniers
|
|
WO2008086807A2
(fr)
*
|
2007-01-19 |
2008-07-24 |
Exiqon A/S |
Apport cellulaire médié d'oligonucléotides de lna
|
|
WO2008094945A2
(fr)
|
2007-01-29 |
2008-08-07 |
Isis Pharmaceuticals, Inc. |
Composes et procedes pour moduler l'expression des proteines
|
|
NZ578980A
(en)
|
2007-02-22 |
2012-03-30 |
Genentech Inc |
Methods for detecting inflammatory bowel disease
|
|
AP3018A
(en)
|
2007-03-29 |
2014-10-31 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expressionof a gene from the ebola
|
|
US20100196455A1
(en)
*
|
2007-05-04 |
2010-08-05 |
Transave, Inc. |
Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
|
|
US9114081B2
(en)
|
2007-05-07 |
2015-08-25 |
Insmed Incorporated |
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
|
US9333214B2
(en)
|
2007-05-07 |
2016-05-10 |
Insmed Incorporated |
Method for treating pulmonary disorders with liposomal amikacin formulations
|
|
WO2008141278A1
(fr)
*
|
2007-05-11 |
2008-11-20 |
Centocor, Inc. |
Méthode de préparation de conjugués d'anticorps
|
|
AR066984A1
(es)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
|
WO2009011855A2
(fr)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Sélection de domaines de capteur à base d'acide nucléique dans une plate-forme d'échange d'acide nucléique
|
|
CN101765616A
(zh)
*
|
2007-07-26 |
2010-06-30 |
巴斯夫欧洲公司 |
制备通过接枝聚合在溶液中获得的并基于固体聚醚的共聚物的方法
|
|
US7960336B2
(en)
*
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
|
EP2177230A4
(fr)
*
|
2007-08-09 |
2011-04-27 |
Daiichi Sankyo Co Ltd |
Immunoliposome induisant l'apoptose dans une cellule exprimant un récepteur comportant le domaine apoptotique
|
|
US8563527B2
(en)
*
|
2007-08-20 |
2013-10-22 |
Pharmain Corporation |
Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
|
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
|
US8865667B2
(en)
*
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
|
EP2197917A1
(fr)
|
2007-09-28 |
2010-06-23 |
Universitätsspital Basel |
Immunoliposomes utilisés pour le traitement du cancer
|
|
JP2010539978A
(ja)
|
2007-10-02 |
2010-12-24 |
アムジェン インコーポレイテッド |
マイクロ−ｒｎａおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加
|
|
CN101983241A
(zh)
*
|
2007-11-05 |
2011-03-02 |
波罗的科技发展有限公司 |
带有修饰碱基的寡核苷酸在核酸杂交中的应用
|
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
|
US20090176892A1
(en)
*
|
2008-01-09 |
2009-07-09 |
Pharmain Corporation |
Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
|
|
KR101397407B1
(ko)
|
2008-03-05 |
2014-06-19 |
알닐람 파마슈티칼스 인코포레이티드 |
Ｅｇ5 및 ＶＥＧＦ 유전자의 발현을 억제하기 위한 조성물 및 방법
|
|
EP2105145A1
(fr)
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Procédé pour la libération spécifique dans les muscles d'oligonucléotides conjugués avec des lipides
|
|
KR20100127880A
(ko)
|
2008-04-04 |
2010-12-06 |
카란도 파마슈티칼즈, 인코포레이티드 |
Ｅｐａｓ1 억제제의 조성물 및 용도
|
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
|
US20100003315A1
(en)
|
2008-07-02 |
2010-01-07 |
Willeford Kenneth L |
Method and Composition for the Treatment of Skin Conditions
|
|
WO2010006282A2
(fr)
*
|
2008-07-10 |
2010-01-14 |
Serina Therapeutics, Inc. |
Polyoxazolines avec groupes terminaux inertes, polyoxazolines préparées à partir de groupes initiateurs protégés, et composés en rapport
|
|
WO2010008582A2
(fr)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Système permettant d'administrer un médicament aux cellules phagocytaires
|
|
WO2010017509A1
(fr)
*
|
2008-08-07 |
2010-02-11 |
Isis Pharmaceuticals, Inc. |
Modulation de l'expression de transthyrétine pour le traitement de troubles concernant le système nerveux central (cns)
|
|
EP2331141B1
(fr)
|
2008-08-25 |
2016-01-06 |
Excaliard Pharmaceuticals, Inc. |
Oligonucléotides antissens dirigés contre le facteur de croissance des tissus conjonctifs et utilisation de ceux-ci
|
|
EP2690175B1
(fr)
|
2008-09-02 |
2016-12-28 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés d'inhibition combinée d'expression du gène mutant EGFR et IL-6
|
|
CN108165548B
(zh)
|
2008-09-22 |
2022-10-14 |
菲奥医药公司 |
减小大小的自递送RNAi化合物
|
|
WO2010036962A1
(fr)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions a base de preparation lipidique et methodes destinees a inhiber l'expression d'un gene de serum amyloïde a
|
|
AU2009302217A1
(en)
|
2008-10-09 |
2010-04-15 |
Northeastern University |
Multifunctional self-assembling polymeric nanosystems
|
|
HRP20150796T1
(hr)
|
2008-10-20 |
2015-09-11 |
Alnylam Pharmaceuticals, Inc. |
Pripravci i postupci za inhibiciju ekspresije transtiretina
|
|
MX353900B
(es)
|
2008-11-07 |
2018-02-01 |
Massachusetts Inst Technology |
Lipidoides de aminoalcohol y usos de los mismos.
|
|
US20110237649A1
(en)
|
2008-12-04 |
2011-09-29 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
|
|
CN102317458B
(zh)
|
2008-12-04 |
2018-01-02 |
库尔纳公司 |
通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
|
|
EP2370582B1
(fr)
|
2008-12-04 |
2017-05-10 |
CuRNA, Inc. |
Traitement de maladies liées à un gène suppresseur de tumeur par inhibition d'un transcrit antisens naturel du gène
|
|
CA2746514C
(fr)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arndb cible sur gnaq et procedes pour inhiber l'expression
|
|
WO2010078536A1
(fr)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition de pcsk9 par arni
|
|
CN102439149B
(zh)
|
2009-02-12 |
2018-01-02 |
库尔纳公司 |
通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
|
|
PT2396038E
(pt)
|
2009-02-12 |
2016-02-19 |
Curna Inc |
Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf
|
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
|
WO2010099341A1
(fr)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Composition et procédés d'inhibition de l'expression du gène mig-12
|
|
US20110319317A1
(en)
|
2009-03-04 |
2011-12-29 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
|
|
CN102421900B
(zh)
|
2009-03-12 |
2015-07-22 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法
|
|
EP2228059A1
(fr)
|
2009-03-12 |
2010-09-15 |
Universitätsspital Basel |
Composition chimio-thérapeutique pour le traitement du cancer
|
|
CA2755409C
(fr)
|
2009-03-16 |
2019-04-30 |
Joseph Collard |
Traitement de maladies associees au facteur nucleaire 2 similaire au derive d'erythroide 2 (nrf2) par inhibition de produit de transcription antisens naturel pour nrf2
|
|
JP5904935B2
(ja)
|
2009-03-17 |
2016-04-20 |
クルナ・インコーポレーテッド |
デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療
|
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
|
EP3248618A1
(fr)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Suppression de l'immunité innée permettant l'administration répétée de longues molécules d'arn
|
|
DK2424987T3
(en)
|
2009-05-01 |
2018-02-26 |
Curna Inc |
TREATMENT OF HEMOGLOBIN (HBF / HBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO HBF / HBG
|
|
JP6250930B2
(ja)
|
2009-05-06 |
2017-12-20 |
クルナ・インコーポレーテッド |
トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
|
|
EP2427553A4
(fr)
|
2009-05-06 |
2012-11-07 |
Opko Curna Llc |
Traitement de maladies associées aux gènes du métabolisme et du transport des lipides par inhibition de transcrit antisens naturel d'un gène du métabolisme et du transport des lipides
|
|
ES2664590T3
(es)
|
2009-05-18 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con factores de reprogramación por inhibición del tránscrito antisentido natural a un factor de reprogramación
|
|
CN102549158B
(zh)
|
2009-05-22 |
2017-09-26 |
库尔纳公司 |
通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
|
|
KR101704988B1
(ko)
|
2009-05-28 |
2017-02-08 |
큐알엔에이, 인크. |
항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
|
|
EP2440250A1
(fr)
|
2009-06-11 |
2012-04-18 |
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. |
Liposomes ciblés comportant des biphosphonates contenant n et leurs utilisations
|
|
ES2629339T3
(es)
|
2009-06-16 |
2017-08-08 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
|
|
CN102695797B
(zh)
|
2009-06-16 |
2018-05-25 |
库尔纳公司 |
通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
|
|
ES2618894T3
(es)
|
2009-06-24 |
2017-06-22 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
|
|
KR101807324B1
(ko)
|
2009-06-26 |
2017-12-08 |
큐알엔에이, 인크. |
다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료
|
|
KR101802536B1
(ko)
|
2009-08-05 |
2017-11-28 |
큐알엔에이, 인크. |
인슐린 유전자 (ｉｎｓ)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ｉｎｓ) 관련된 질환의 치료
|
|
US9029338B2
(en)
|
2009-08-14 |
2015-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
CN102482671B
(zh)
|
2009-08-25 |
2017-12-01 |
库尔纳公司 |
通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
|
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
EP3252068B1
(fr)
|
2009-10-12 |
2025-07-02 |
Larry J. Smith |
Procédés et compositions permettant de moduler l'expression génique à l'aide de médicaments à base d'oligonucléotides administrés in vivo ou in vitro
|
|
CA2778442A1
(fr)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Procedes et compositions pour moduler l'activation d'hepsine d'une proteine de stimulation de macrophage
|
|
WO2011056234A1
(fr)
|
2009-11-06 |
2011-05-12 |
Fibrogen, Inc. |
Traitement de troubles induits par un rayonnement
|
|
AU2010324686B2
(en)
|
2009-11-30 |
2016-05-19 |
Genentech, Inc. |
Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
|
|
EP3403647A1
(fr)
|
2009-12-01 |
2018-11-21 |
Translate Bio, Inc. |
Administration d'arnm pour l'augmentation des protéines et des enzymes dans des maladies génétiques humaines
|
|
MX2012006580A
(es)
|
2009-12-11 |
2012-09-28 |
Genecode As |
Metodo para facilitar la sobrevivencia de celulas neurales usando mimeticos de ligandos (gfl) de la familia gdnf o activadores de la ruta de señalizacion de ret.
|
|
KR101823702B1
(ko)
|
2009-12-16 |
2018-01-30 |
큐알엔에이, 인크. |
막 결합 전사 인자 펩티다제, 부위 １(ｍｂｔｐｓ１)에 대한 천연 안티센스 전사체의 억제에 의한 ｍｂｔｐｓ１ 관련 질환의 치료
|
|
KR101793753B1
(ko)
|
2009-12-23 |
2017-11-03 |
큐알엔에이, 인크. |
커플링방지 단백질 ２(ｕｃｐ２)에 대한 천연 안티센스 전사체의 저해에 의한 ｕｃｐ２ 관련 질환의 치료
|
|
DK2516648T3
(en)
|
2009-12-23 |
2018-02-12 |
Curna Inc |
TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF
|
|
ES2657452T3
(es)
|
2009-12-29 |
2018-03-05 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor respiratorio nuclear 1 (NRF1) mediante inhibición de transcrito antisentido natural a NRF1
|
|
CN102770540B
(zh)
|
2009-12-29 |
2017-06-23 |
库尔纳公司 |
通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病
|
|
DK2521784T3
(en)
|
2010-01-04 |
2018-03-12 |
Curna Inc |
TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
|
|
WO2011085066A2
(fr)
|
2010-01-06 |
2011-07-14 |
Curna, Inc. |
Traitement de maladies associées à un gène de développement pancréatique par inhibition du produit de la transcription anti-sens naturel en un gène de développement pancréatique
|
|
CA2786535C
(fr)
|
2010-01-11 |
2019-03-26 |
Curna, Inc. |
Traitement des maladies associees a la globuline se liant aux hormones sexuelles (shbg) par inhibition du produit de transcription anti-sens naturel en shbg
|
|
WO2011090971A2
(fr)
|
2010-01-19 |
2011-07-28 |
The Trustees Of Columbia University In The City Of New York |
Emploi de l'ostéocalcine dans le traitement de troubles de la reproduction chez le mâle
|
|
US8946182B2
(en)
|
2010-01-25 |
2015-02-03 |
Curna, Inc. |
Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
|
|
EP2531175A2
(fr)
|
2010-02-01 |
2012-12-12 |
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. |
Liposomes comprenant des médicaments amphipathiques et procédé pour leur préparation
|
|
JP5976548B2
(ja)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー，インコーポレイテッド |
Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療
|
|
MX2012009215A
(es)
|
2010-02-23 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
|
JP5860029B2
(ja)
|
2010-03-29 |
2016-02-16 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
トランスチレチン（ＴＴＲ）関連眼アミロイドーシスのためのｓｉＲＮＡ療法
|
|
CA2792561C
(fr)
|
2010-04-06 |
2021-10-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procedes permettant d'inhiber l'expression du gene cd274/pd-l1
|
|
US9044494B2
(en)
|
2010-04-09 |
2015-06-02 |
Curna, Inc. |
Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
|
|
NZ603339A
(en)
|
2010-04-29 |
2015-01-30 |
Isis Pharmaceuticals Inc |
Modulation of transthyretin expression
|
|
US9089588B2
(en)
|
2010-05-03 |
2015-07-28 |
Curna, Inc. |
Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
|
|
MX342239B
(es)
|
2010-05-03 |
2016-09-21 |
Genentech Inc * |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
|
CN103429739B
(zh)
|
2010-05-12 |
2018-11-13 |
哥伦比亚大学纽约管理委员会 |
制备产生和分泌胰岛素的肠内分泌细胞的方法
|
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
EP3299464B1
(fr)
|
2010-05-26 |
2019-10-02 |
CuRNA, Inc. |
Traitement de maladies associées à l'homologue atonal 1 par inhibition du produit de transcription antisens naturel d'atoh1
|
|
EP3456827A3
(fr)
|
2010-06-02 |
2019-05-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés permettant de traiter la fibrose du foie
|
|
MX2013000250A
(es)
|
2010-07-02 |
2013-10-28 |
Angiochem Inc |
Polipeptidos cortos y que contienen d-aminoacido para conjugados terapeuticos y usos de los mismos.
|
|
CN103068982B
(zh)
|
2010-07-14 |
2017-06-09 |
库尔纳公司 |
通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
|
|
WO2012027675A2
(fr)
|
2010-08-26 |
2012-03-01 |
Massachusetts Institute Of Technology |
Poly(bêta-amino-alcools), leur préparation et utilisations de ceux-ci
|
|
EP2625197B1
(fr)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Mutant smoothened et ses procédés d'utilisation
|
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
|
US20140086975A1
(en)
|
2010-10-15 |
2014-03-27 |
Rutgers, The State University Of New Jersey |
Hydrogel formulation for dermal and ocular delivery
|
|
WO2012054723A2
(fr)
|
2010-10-22 |
2012-04-26 |
Opko Curna Llc |
Traitement de maladies associées à l'alpha-l-iduronidase (idua) par inhibition du transcrit antisens endogène de idua
|
|
JP6073795B2
(ja)
|
2010-10-27 |
2017-02-01 |
カッパーアールエヌエー，インコーポレイテッド |
インターフェロン関連発生制御因子１（ｉｆｒｄ１）への天然アンチセンス転写物の阻害によるｉｆｒｄ１関連疾患の治療
|
|
US20140134181A1
(en)
|
2010-11-05 |
2014-05-15 |
Kenneth E. Lipson |
Treatment Method For Lung Remodeling Diseases
|
|
CN103370054A
(zh)
|
2010-11-09 |
2013-10-23 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
|
WO2012065044A2
(fr)
|
2010-11-12 |
2012-05-18 |
Purdue Research Foundation |
Traitement de cellules tumorales de la vessie à l'aide de la protéine de liaison à la fibronectine comme cible
|
|
EP2643463B1
(fr)
|
2010-11-23 |
2017-09-27 |
CuRNA, Inc. |
Traitement de maladies associées à nanog par l'inhibition d'un transcript antisens naturel de nanog
|
|
US9127275B2
(en)
|
2010-12-10 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
|
EP2649182A4
(fr)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
Compositions et procédés pour l'augmentation de la production d'érythropoïétine (epo)
|
|
CA2834968C
(fr)
|
2011-01-05 |
2018-01-09 |
Livon Laboratories |
Procedes de fabrication de liposomes, compositions a base de liposomes preparees en utilisant les procedes, et procedes d'utilisation associes
|
|
US20140227343A1
(en)
*
|
2011-01-31 |
2014-08-14 |
Centre National De La Recherche Scientifique |
Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
|
|
MX365647B
(es)
|
2011-02-02 |
2019-06-10 |
Excaliard Pharmaceuticals Inc |
El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.
|
|
ES2634669T3
(es)
|
2011-02-08 |
2017-09-28 |
Halozyme, Inc. |
Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
|
|
WO2012109495A1
(fr)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cibles cellulaires de thiazolidinediones
|
|
US8679531B2
(en)
*
|
2011-03-02 |
2014-03-25 |
Ananth Annapragada |
Vesicle compositions
|
|
US9238716B2
(en)
|
2011-03-28 |
2016-01-19 |
Massachusetts Institute Of Technology |
Conjugated lipomers and uses thereof
|
|
CN113736782B
(zh)
|
2011-03-29 |
2024-07-16 |
阿尔尼拉姆医药品有限公司 |
用于抑制tmprss6基因表达的组合物和方法
|
|
EP2508176A1
(fr)
|
2011-04-08 |
2012-10-10 |
Lipotarg Gmbh |
Nouveau traitement combiné du cancer
|
|
JP5951752B2
(ja)
|
2011-04-13 |
2016-07-13 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ｐｔｐ１ｂ発現のアンチセンス調節
|
|
AU2012254842A1
(en)
*
|
2011-05-12 |
2013-05-02 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Liposomes comprising polymer-conjugated lipids and related uses
|
|
EP2714892B1
(fr)
|
2011-06-02 |
2018-02-21 |
President and Fellows of Harvard College |
Procédés et utilisations associées à des systemes de culture tissulaire ex vivo
|
|
US20140206753A1
(en)
|
2011-06-08 |
2014-07-24 |
Shire Human Genetic Therapies, Inc. |
Lipid nanoparticle compositions and methods for mrna delivery
|
|
EP2718439B1
(fr)
|
2011-06-09 |
2017-08-09 |
CuRNA, Inc. |
Traitement des maladies associées à la frataxine (fxn) par inhibition de la transcription de l'anti-sens naturel de la fxn
|
|
CA2839437A1
(fr)
|
2011-06-16 |
2012-12-20 |
Isis Pharmaceuticals, Inc. |
Modulation antisens de l'expression du recepteur 4 du facteur de croissance fibroblastique
|
|
MX344807B
(es)
|
2011-06-21 |
2017-01-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3).
|
|
CA2839896A1
(fr)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Dosages et procedes de determination de l'activite d'un agent therapeutique chez un sujet
|
|
EP2723351B1
(fr)
|
2011-06-21 |
2018-02-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés d'inhibition de l'expression de gènes de protéine c (proc)
|
|
EP3366312A1
(fr)
|
2011-06-23 |
2018-08-29 |
Alnylam Pharmaceuticals, Inc. |
Arnsi de serpina 1 : compositions de matière et procédés de traitement
|
|
CN103765212A
(zh)
|
2011-06-27 |
2014-04-30 |
杰克逊实验室 |
治疗癌症和自体免疫性疾病的方法和组合物
|
|
HRP20201465T1
(hr)
|
2011-07-13 |
2021-02-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Liposomi koji ko-inkapsuliraju bisfosfonat i amfipatsko sredstvo
|
|
WO2013019857A2
(fr)
|
2011-08-01 |
2013-02-07 |
Alnylam Pharmaceuticals, Inc. |
Procédé permettant d'améliorer le taux de succès des greffes de cellules souches hématopoïétiques
|
|
CN108410868A
(zh)
|
2011-09-20 |
2018-08-17 |
Ionis制药公司 |
Gcgr表达的反义调节
|
|
DK2758074T3
(da)
|
2011-09-23 |
2020-07-27 |
Univ Loma Linda |
Bakteriestammer der udtrykker methylasegener og anvendelser deraf
|
|
WO2013047263A1
(fr)
*
|
2011-09-28 |
2013-04-04 |
テルモ株式会社 |
Liposome contenant de l'hémoglobine et son procédé de production
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
MX350944B
(es)
|
2011-10-25 |
2017-09-26 |
Ionis Pharmaceuticals Inc |
Modulación antisentido de la expresión de gccr.
|
|
MX362089B
(es)
|
2011-12-16 |
2019-01-07 |
Nanobiotix |
Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos.
|
|
WO2013114377A1
(fr)
|
2012-02-02 |
2013-08-08 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd |
Liposomes stables pour l'administration de médicament
|
|
HK1210211A1
(en)
|
2012-03-15 |
2016-04-15 |
科纳公司 |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
MX369828B
(es)
|
2012-05-21 |
2019-11-22 |
Insmed Inc |
Sistemas para tratar infecciones pulmonares.
|
|
EP2859102A4
(fr)
|
2012-06-08 |
2016-05-11 |
Shire Human Genetic Therapies |
Polynucléotides résistant à la nucléase et leurs utilisations
|
|
WO2014028487A1
(fr)
|
2012-08-13 |
2014-02-20 |
Massachusetts Institute Of Technology |
Lipidoïdes contenant des amines et leurs utilisations
|
|
WO2014041179A1
(fr)
|
2012-09-17 |
2014-03-20 |
Chemedest Ltd. |
Traitement d'une neuropathie périphérique à l'aide d'agonistes du récepteur de type 3 de gfr(alpha)3
|
|
ES2743039T3
(es)
|
2012-11-29 |
2020-02-18 |
Insmed Inc |
Formulaciones de vancomicina estabilizada
|
|
AU2013360302C1
(en)
|
2012-12-12 |
2019-01-24 |
Temple University - Of The Commonwealth System Of Higher Education |
Compositions and methods for treatment of cancer
|
|
ES2847930T3
(es)
|
2013-01-07 |
2021-08-04 |
Mucosal Vaccine Tech Llc |
Vacunas terapéuticas para el tratamiento de las infecciones por el virus del herpes simple de tipo 2
|
|
CA2904151C
(fr)
|
2013-03-14 |
2023-09-12 |
Shire Human Genetic Therapies, Inc. |
Composition a base d'arnm du gene cftr et procedes et utilisations associes
|
|
ES2981185T3
(es)
|
2013-03-14 |
2024-10-07 |
Translate Bio Inc |
Métodos para la purificación de ARN mensajero
|
|
CA2902565C
(fr)
|
2013-03-15 |
2022-11-29 |
Loma Linda University |
Traitement de maladies auto-immunes
|
|
US10052364B2
(en)
|
2013-03-15 |
2018-08-21 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
|
WO2014160871A2
(fr)
|
2013-03-27 |
2014-10-02 |
The General Hospital Corporation |
Procédés et agents pour le traitement de la maladie d'alzheimer
|
|
WO2014179562A1
(fr)
|
2013-05-01 |
2014-11-06 |
Massachusetts Institute Of Technology |
Dérivés de 1,3,5-triazinane-2,4,6-trione et leurs utilisations
|
|
US10246708B2
(en)
|
2013-05-06 |
2019-04-02 |
Alnylam Pharmaceuticals, Inc. |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
|
DK3007704T3
(da)
|
2013-06-13 |
2021-03-29 |
Antisense Therapeutics Ltd |
Kombinationsterapi til akromegali
|
|
US9827552B2
(en)
|
2013-07-17 |
2017-11-28 |
Clemson University |
Functionalized lipid modification of solid phase surfaces for use in chromatography
|
|
CN105793422B
(zh)
|
2013-09-05 |
2020-03-03 |
萨罗塔治疗公司(美国) |
酸性α-葡糖苷酶中反义诱导的外显子2纳入
|
|
EP3047023B1
(fr)
|
2013-09-19 |
2019-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions et méthodes d'inhibition du virus jc (jcv)
|
|
US10077444B2
(en)
|
2013-10-02 |
2018-09-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
ES2804510T3
(es)
|
2013-10-04 |
2021-02-08 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión del gen ALAS1
|
|
WO2015061491A1
(fr)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Thérapie à l'arnm pour la phénylcétonurie
|
|
BR112016009014B1
(pt)
|
2013-10-22 |
2024-02-06 |
Translate Bio, Inc |
USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
|
|
MX2016005238A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
|
|
WO2015116902A1
(fr)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
Récepteurs couplés aux protéines g dans la signalisation hedgehog
|
|
WO2015120075A2
(fr)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened et méthodes d'utilisation de celui-ci
|
|
DK3134068T3
(da)
|
2014-04-21 |
2021-10-04 |
Heron Therapeutics Inc |
Langtidsvirkende polymerafgivelsessystemer
|
|
WO2018048460A1
(fr)
|
2014-04-21 |
2018-03-15 |
Heron Therapeutics, Inc. |
Composition pharmaceutique comprenant un système d'administration, un anesthésique local de type amide et un méloxicam
|
|
MX373952B
(es)
|
2014-04-25 |
2020-07-13 |
Shire Human Genetic Therapies |
Métodos de purificación de arn mensajero.
|
|
WO2015171918A2
(fr)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions et leurs utilisations thérapeutiques
|
|
EP3466432B1
(fr)
|
2014-05-15 |
2020-07-08 |
Insmed Incorporated |
Méthodes de traitement d'infections pulmonaires mycobactériennes non-tuberculeuses
|
|
CN106659731A
(zh)
|
2014-05-30 |
2017-05-10 |
夏尔人类遗传性治疗公司 |
用于递送核酸的可生物降解脂质
|
|
UA121863C2
(uk)
|
2014-06-24 |
2020-08-10 |
Транслейт Байо, Інк. |
Стереохімічно збагачені композиції для доставки нуклеїнових кислот
|
|
WO2015200901A1
(fr)
|
2014-06-26 |
2015-12-30 |
The Trustees Of Columbia University In The City Of New York |
L'inhibition de l'expression de la sérotonine dans des cellules entéroendocrines intestinales provoque leur conversion en cellules positives pour l'insuline
|
|
US9840479B2
(en)
|
2014-07-02 |
2017-12-12 |
Massachusetts Institute Of Technology |
Polyamine-fatty acid derived lipidoids and uses thereof
|
|
HRP20190881T1
(hr)
|
2014-08-28 |
2019-07-12 |
Halozyme, Inc. |
Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
|
|
WO2016033424A1
(fr)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Méthodes de prévention et de traitement d'évènements indésirables cardiovasculaires majeurs à l'aide de composés modulant l'apolipoprotéine b
|
|
WO2016081728A1
(fr)
|
2014-11-19 |
2016-05-26 |
The Trustees Of Columbia University In The City Of New York |
Ostéocalcine comme traitement de fragilité associée au vieillissement
|
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
|
WO2016100716A1
(fr)
|
2014-12-18 |
2016-06-23 |
Vasant Jadhav |
Composés reversirtm
|
|
WO2016118476A1
(fr)
|
2015-01-20 |
2016-07-28 |
The Children's Medical Center Corporation |
Composés anti-net pour traiter ou prévenir la fibrose et pour faciliter la cicatrisation des plaies
|
|
JP6859275B2
(ja)
|
2015-03-17 |
2021-04-14 |
リポメディックス・ファーマシューティカルズ・リミテッドＬｉｐｏｍｅｄｉｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． |
膀胱がんの治療方法
|
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
EA201792560A1
(ru)
|
2015-05-28 |
2018-06-29 |
Нанобиотикс |
Наночастицы для применения в качестве терапевтической вакцины
|
|
WO2016196670A1
(fr)
|
2015-06-01 |
2016-12-08 |
Sarepta Therapeutics, Inc. |
Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
|
|
MX2018000016A
(es)
|
2015-07-02 |
2019-01-31 |
Otsuka Pharma Co Ltd |
Composiciones farmaceuticas liofilizadas.
|
|
CA3205381A1
(fr)
|
2015-07-17 |
2017-01-26 |
Alnylam Pharmaceuticals, Inc. |
Conjugues constitues d'une entite unique a cibles multiples
|
|
EP3335028A1
(fr)
|
2015-08-11 |
2018-06-20 |
Scintillon Institute for Biomedical and Bioenergy Research |
Analyse optique de particules et de vésicules
|
|
TW201718857A
(zh)
|
2015-09-14 |
2017-06-01 |
艾爾妮蘭製藥公司 |
用於抑制alas1基因表現之組合物及方法
|
|
US10954300B2
(en)
|
2015-09-28 |
2021-03-23 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
|
MA45819A
(fr)
|
2015-10-09 |
2018-08-15 |
Sarepta Therapeutics Inc |
Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
|
|
BR112018006922B1
(pt)
|
2015-10-16 |
2023-11-21 |
Ipsen Biopharm Ltd |
Composições de irinotecano lipossômico estabilizado para armazenamento
|
|
WO2017075670A1
(fr)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
Mobilisation de cellules leucémiques
|
|
EP3373910B1
(fr)
|
2015-11-10 |
2023-07-12 |
Children's Research Institute, Children's National Medical Center |
Formulation d'échinomycine, procédé de fabrication et méthode d'utilisation de cette dernière
|
|
JP7412079B2
(ja)
|
2015-12-23 |
2024-01-12 |
レプルカ プロプライアタリー リミティド |
核酸オリゴマーとその用途
|
|
EP3445405A4
(fr)
|
2016-04-18 |
2019-12-18 |
Sarepta Therapeutics, Inc. |
Oligomères antisens et procédés d'utilisation de ceux-ci pour le traitement de maladies associées au gène de l'alpha-glucosidase acide
|
|
MX2019010155A
(es)
|
2017-02-27 |
2020-12-10 |
Translate Bio Inc |
Arnm de cftr optimizado por codón novedoso.
|
|
BR112019017103A2
(pt)
|
2017-03-10 |
2020-04-14 |
Quiapeg Pharmaceuticals Ab |
conjugados liberáveis
|
|
CA3056797A1
(fr)
|
2017-03-16 |
2018-09-20 |
Children's Medical Center Corporation |
Liposomes ingenierises utilises en tant qu'agents therapeutiques ciblant le cancer
|
|
US10994025B2
(en)
|
2017-05-12 |
2021-05-04 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded RNA complexes and uses related thereto
|
|
MA49138A
(fr)
|
2017-05-16 |
2020-03-25 |
Translate Bio Inc |
Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
|
|
CR20190572A
(es)
|
2017-07-06 |
2020-05-23 |
Arrowhead Pharmaceuticals Inc |
AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
|
|
MX2020001233A
(es)
|
2017-08-03 |
2020-07-20 |
Otsuka Pharma Co Ltd |
Compuesto farmaceutico y metodos de purificacion del mismo.
|
|
WO2019055460A1
(fr)
|
2017-09-13 |
2019-03-21 |
The Children's Medical Center Corporation |
Compositions et méthodes pour le traitement de maladies associées aux transposons
|
|
US11555189B2
(en)
|
2017-10-18 |
2023-01-17 |
Sarepta Therapeutics, Inc. |
Antisense oligomer compounds
|
|
US11344497B1
(en)
|
2017-12-08 |
2022-05-31 |
Quicksilver Scientific, Inc. |
Mitochondrial performance enhancement nanoemulsion
|
|
US10722465B1
(en)
|
2017-12-08 |
2020-07-28 |
Quicksilber Scientific, Inc. |
Transparent colloidal vitamin supplement
|
|
WO2019152563A1
(fr)
|
2018-01-30 |
2019-08-08 |
Life Technologies Corporation |
Instruments, dispositifs et consommables destinés à être utilisés dans le flux de travail d'un système d'analyse moléculaire intelligent
|
|
EP3762037B1
(fr)
|
2018-03-09 |
2023-12-27 |
QuiaPEG Pharmaceuticals AB |
Conjugués d'anticorps libérables
|
|
WO2019183320A1
(fr)
|
2018-03-21 |
2019-09-26 |
Colorado State University Research Foundation |
Compositions de vaccins contre le cancer et leurs méthodes d'utilisation
|
|
WO2019191627A1
(fr)
|
2018-03-30 |
2019-10-03 |
Insmed Incorporated |
Procédés pour la fabrication continue de produits médicamenteux liposomaux
|
|
WO2019195738A1
(fr)
|
2018-04-06 |
2019-10-10 |
Children's Medical Center Corporation |
Compositions et procédés de reprogrammation de cellules somatiques et de modulation d'impression
|
|
EP3837367A1
(fr)
|
2018-08-16 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés d'inhibition de l'expression du gène lect2
|
|
WO2020041793A1
(fr)
|
2018-08-24 |
2020-02-27 |
Translate Bio, Inc. |
Procédés de purification d'arn messager
|
|
CA3112473A1
(fr)
|
2018-09-12 |
2020-03-19 |
Quiapeg Pharmaceuticals Ab |
Conjugues de glp-1 liberables
|
|
AU2019384557B2
(en)
|
2018-11-21 |
2025-07-17 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
|
|
WO2020113135A1
(fr)
|
2018-11-29 |
2020-06-04 |
Flagship Pioneering Innovations V, Inc. |
Procédés pour moduler l'arn
|
|
KR20210134339A
(ko)
|
2019-02-25 |
2021-11-09 |
노파르티스 아게 |
바이러스 전달을 위한 메조다공성 실리카 입자 조성물
|
|
US11291702B1
(en)
|
2019-04-15 |
2022-04-05 |
Quicksilver Scientific, Inc. |
Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
|
|
WO2020259670A1
(fr)
*
|
2019-06-28 |
2020-12-30 |
江苏恒瑞医药股份有限公司 |
Composition lipidique à libération prolongée et son procédé de préparation
|
|
CN114616331B
(zh)
|
2019-09-03 |
2024-10-22 |
阿尔尼拉姆医药品有限公司 |
抑制lect2基因表达的组合物和方法
|
|
EP4038189A1
(fr)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions et méthodes pour le silençage de l'expression génique de l'ugt1a1
|
|
WO2021087325A1
(fr)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions et méthodes pour rendre silencieuse l'expression du gène de fusion dnajb1-prkaca
|
|
TW202140786A
(zh)
|
2020-02-10 |
2021-11-01 |
美商艾爾妮蘭製藥公司 |
用於靜默ｖｅｇｆ－ａ表現之組合物及方法
|
|
EP4114456A1
(fr)
|
2020-03-06 |
2023-01-11 |
The Colorado State University Research Foundation |
Production de vaccins comprenant des particules virales de sras-cov-2 inactivées
|
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
BR112022020145A2
(pt)
|
2020-04-06 |
2023-01-03 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para silenciamento da expressão de myoc
|
|
BR112022020227A2
(pt)
|
2020-04-07 |
2022-11-22 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para silenciamento da expressão de scn9a
|
|
US20230183707A1
(en)
|
2020-05-21 |
2023-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
EP4649951A2
(fr)
|
2020-06-09 |
2025-11-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arnsi et procédés pour le silençage de l'expression de l'antigène (glycérol-3-phosphate acyltransférase 1, mitochondriale)
|
|
US20230302155A1
(en)
|
2020-08-21 |
2023-09-28 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
WO2022226291A1
(fr)
|
2021-04-22 |
2022-10-27 |
Dana-Farber Cancer Institute, Inc. |
Compositions et méthodes pour traiter le cancer
|
|
JP2024527584A
(ja)
|
2021-07-09 |
2024-07-25 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
ＣＮＳ送達のためのＢｉｓ－ＲＮＡｉ化合物
|
|
US20250034567A1
(en)
|
2021-08-31 |
2025-01-30 |
Alnylam Pharmaceuticals, Inc. |
Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
|
|
AU2023314797A1
(en)
|
2022-07-29 |
2024-12-12 |
Repertoire Immune Medicines, Inc. |
T cell epitopes associated with type 1 diabetes
|
|
EP4569113A1
(fr)
|
2022-09-15 |
2025-06-18 |
Regeneron Pharmaceuticals, Inc. |
Compositions d'arni de 17b-hydroxystéroïde déshydrogénase de type 13 (hsd17b13) et leurs procédés d'utilisation
|
|
KR20250144467A
(ko)
|
2023-02-09 |
2025-10-10 |
알닐람 파마슈티칼스 인코포레이티드 |
Reversir 분자 및 이의 사용 방법
|
|
WO2025072849A1
(fr)
|
2023-09-29 |
2025-04-03 |
Repertoire Immune Medicines, Inc. |
Peptides présentables par le cmh associés au diabète de type 1
|